Face-Off: DF/MGH/HCC vs. YALE

home / face-off / face-off-df-mgh-hcc-vs-yale

A team of experts discuss multiple topics related to non-small cell lung cancer.

Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate

EP. 1: Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 7th 2023

Highlight on the debate format, speakers, and direction to support the discussion.

Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC

EP. 2: Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 7th 2023

The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study

EP. 3: Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 14th 2023

A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study

KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

EP. 4: KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 14th 2023

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial

EP. 5: Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 21st 2023

A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial

EP. 6: Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 21st 2023

An overview of results from the phase III randomized ADAURA Trial.

Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study

EP. 7: Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 28th 2023

Dr. Herbst discusses the CHRYSALIS Phase 1 trial.

Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC

EP. 8: Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
December 28th 2023

Dr. Florez leads the discussion on the association between Medicaid insurance, biomarker testing, and the outcomes in patients with advanced NSCLC.

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC

EP. 9: Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
January 4th 2024

A debate presented on liquid biopsy versus tissue biopsy to determine front line therapy in metastatic NSCLC.

Face-Off: Award Presentations and Event Conclusion

EP. 10: Face-Off: Award Presentations and Event Conclusion

Jia Luo, MD;Narjust Florez, MD;Justin Gainor, MD;Scott J. Swanson, MD;Anne Chiang, MD ;Roy S. Herbst, MD, PhD;So Yeon Kim, MD;Justin Blasberg, MD, MPH, FACS
January 4th 2024

Judy concludes the event and presents the awards.